Search

everythinglearnresearchcommunity

for

Search:↓

Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.

A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.

Sodium valproate is not recommended as a first-line treatment for neuropathy but may be used in resistant cases.

Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.

Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.

Betulinic acid can help treat hepatitis C by stopping virus replication.

A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Nilotinib can cause generalized keratosis pilaris.

A woman lost her hair after taking acyclovir, but it grew back when she stopped the medication.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

Most patients on this hepatitis C treatment experienced skin issues, especially hair loss.

Levetiracetam often causes behavioral issues, while oxcarbazepine is more likely to cause sleepiness in epilepsy patients.

Cepharanthine could be a strong antiviral against COVID-19.

Antiepileptic drugs can cause side effects like menstrual problems and infertility in women with epilepsy, but most pregnancies result in healthy babies, with newer drugs being safer.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.

A man with HIV developed skin and hair issues after starting HIV treatment, which improved with topical treatment.

Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.

Sodium valproate is a safe and effective epilepsy drug with manageable side effects.

Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Six African American women experienced hair loss after switching to a new HIV medication.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.

Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.

A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.